D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$728M |
| 2 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$625M |
| 3 |
Merck
MRK
|
+$498M |
| 4 |
Bank of America
BAC
|
+$487M |
| 5 |
Fortinet
FTNT
|
+$321M |
Top Sells
| 1 |
Tesla
TSLA
|
+$696M |
| 2 |
Adobe
ADBE
|
+$610M |
| 3 |
Accenture
ACN
|
+$518M |
| 4 |
Microsoft
MSFT
|
+$495M |
| 5 |
Broadcom
AVGO
|
+$471M |
Sector Composition
| 1 | Technology | 22.95% |
| 2 | Consumer Discretionary | 14.11% |
| 3 | Healthcare | 10.4% |
| 4 | Financials | 9.83% |
| 5 | Industrials | 7.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Terns Pharmaceuticals
TERN
$656M
| $313K | ﹤0.01% |
37,471
+10,506
| +39% | +$87.6K |
|
2527
Essential Properties Realty Trust
EPRT
$5.9B
| $309K | ﹤0.01% |
+9,057
| New | +$309K |
|
2528
Topgolf Callaway Brands
MODG
$1.74B
| $309K | ﹤0.01% |
+28,129
| New | +$309K |
|
2529
Surgery Partners
SGRY
$2.82B
| $307K | ﹤0.01% |
9,537
-147,732
| -94% | -$4.76M |
|
2530
VanEck Rare Earth/Strategic Metals ETF
REMX
$731M
| $307K | ﹤0.01% |
+6,657
| New | +$307K |
|
2531
Olema Pharmaceuticals
OLMA
$564M
| $306K | ﹤0.01% |
25,593
+4,534
| +22% | +$54.1K |
|
2532
Fresenius Medical Care
FMS
$14.7B
| $305K | ﹤0.01% |
+14,340
| New | +$305K |
|
2533
AngloGold Ashanti
AU
$32.7B
| $305K | ﹤0.01% |
11,452
-19,390
| -63% | -$516K |
|
2534
NewAmsterdam Pharma
NAMS
$2.95B
| $305K | ﹤0.01% |
+18,345
| New | +$305K |
|
2535
Vanguard Russell 1000 Value ETF
VONV
$13.6B
| $304K | ﹤0.01% |
3,646
-18,341
| -83% | -$1.53M |
|
2536
Vanguard Russell 1000 Growth ETF
VONG
$31.8B
| $303K | ﹤0.01% |
+3,142
| New | +$303K |
|
2537
American Axle
AXL
$727M
| $303K | ﹤0.01% |
48,990
-120,415
| -71% | -$744K |
|
2538
Harmony Gold Mining
HMY
$9.47B
| $302K | ﹤0.01% |
29,710
+15,713
| +112% | +$160K |
|
2539
Howard Hughes
HHH
$4.82B
| $301K | ﹤0.01% |
3,881
-28,377
| -88% | -$2.2M |
|
2540
BlackRock Capital Allocation Term Trust
BCAT
$1.59B
| $300K | ﹤0.01% |
18,238
-9,660
| -35% | -$159K |
|
2541
Cavco Industries
CVCO
$4.39B
| $299K | ﹤0.01% |
699
| – | – |
|
2542
Liquidity Services
LQDT
$847M
| $298K | ﹤0.01% |
+13,086
| New | +$298K |
|
2543
United Bankshares
UBSI
$5.36B
| $297K | ﹤0.01% |
8,015
-47,655
| -86% | -$1.77M |
|
2544
Capital Group Growth ETF
CGGR
$16B
| $297K | ﹤0.01% |
+8,544
| New | +$297K |
|
2545
Ameren
AEE
$27.1B
| $295K | ﹤0.01% |
3,374
-53,907
| -94% | -$4.71M |
|
2546
Willis Towers Watson
WTW
$32.9B
| $295K | ﹤0.01% |
1,000
-100
| -9% | -$29.5K |
|
2547
Global X Genomics & Biotechnology ETF
GNOM
$45.8M
| $294K | ﹤0.01% |
6,526
+1,464
| +29% | +$65.9K |
|
2548
ONE Gas
OGS
$4.52B
| $294K | ﹤0.01% |
3,945
-400
| -9% | -$29.8K |
|
|
BCPC
2549
Balchem Corporation
BCPC
$5.12B
| $293K | ﹤0.01% |
1,667
| – | – |
|
2550
Douglas Dynamics
PLOW
$762M
| $292K | ﹤0.01% |
10,575
-84,370
| -89% | -$2.33M |
|